Clinical Trials
41 trialsIRONMAN
Prostate Cancer Clinical Trials Consortium
China Metastatic Liver Cancer Clinical Registry Cohort Database
Anhui Provincial Hospital
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
ELENI
iOMEDICO AG
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
M.D. Anderson Cancer Center
Real-world Association Between Concomitant Beta-blocker Exposure and Anti-PD-1/PD-L1 Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
Affiliated Hospital of Nantong University
BIOMATCH
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
HERO
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Early Recovery After Surgery Protocol in Improving Quality of Life in Participants With Stage 0-IIIC Gastric Cancer Undergoing Surgery
City of Hope Medical Center
TOX-FRAIL
Ankara Etlik City Hospital
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
M.D. Anderson Cancer Center
PROOF
University of California, San Francisco
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Medical College of Wisconsin
African Cancer Genome: GMD
Fox Chase Cancer Center
PainSomnia
Germans Trias i Pujol Hospital
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
HUTCH
University of Alabama at Birmingham
PDxBRUTILITY
Precise Dx, Inc.
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Pfizer
Increasing Oral Medication Adherence for Metastatic Breast Cancer Patients
European Institute of Oncology
EPI VITRAKVI
Bayer
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer
Prosquare
Universitaire Ziekenhuizen KU Leuven
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Pfizer
Perioperative Care in the Cancer Patient -1, ARCA-1 Study
M.D. Anderson Cancer Center
IL
Aura Biosciences
ADTCR
Rennes University Hospital
GURC
Janssen Inc.
CNA TVES
Assistance Publique - Hôpitaux de Paris
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
Shengjing Hospital
6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PIPER
Cerus Corporation
SURPASSe
Assistance Publique - Hôpitaux de Paris
Mascot
Royal Free Hospital NHS Foundation Trust
RADIANCE
AstraZeneca
Sleep and Survival in Colorectal Cancer
Zealand University Hospital
BCT
The Methodist Hospital Research Institute
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
ChineseAMS
Testing a Personalize Medication Log for Patients With Lymphoma
Memorial Sloan Kettering Cancer Center
TRAFIC
Merck Sharp & Dohme LLC
LCCM-Control
Lancaster General Hospital